Bruker Co. (BRKR) Given Average Rating of “Hold” by Analysts
Bruker Co. (NASDAQ:BRKR) has been given an average rating of “Hold” by the eleven ratings firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $34.38.
A number of equities analysts have commented on the stock. BidaskClub downgraded shares of Bruker from a “buy” rating to a “hold” rating in a report on Wednesday, June 20th. Morgan Stanley downgraded shares of Bruker from an “equal weight” rating to an “underweight” rating and lifted their price objective for the stock from $31.00 to $32.00 in a report on Thursday, September 20th. Zacks Investment Research downgraded shares of Bruker from a “buy” rating to a “hold” rating in a report on Friday, June 8th. Finally, ValuEngine downgraded shares of Bruker from a “buy” rating to a “hold” rating in a report on Friday, September 21st.
A number of institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new position in shares of Bruker during the second quarter valued at $101,000. Sun Life Financial INC acquired a new position in shares of Bruker during the second quarter valued at $163,000. TLP Group LLC acquired a new position in shares of Bruker during the first quarter valued at $190,000. Strs Ohio acquired a new position in shares of Bruker during the second quarter valued at $327,000. Finally, State of Alaska Department of Revenue boosted its holdings in shares of Bruker by 35.6% during the second quarter. State of Alaska Department of Revenue now owns 11,510 shares of the medical research company’s stock valued at $334,000 after acquiring an additional 3,020 shares during the period. 65.61% of the stock is owned by hedge funds and other institutional investors.
Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, August 2nd. The medical research company reported $0.25 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.25. The business had revenue of $443.70 million during the quarter, compared to analyst estimates of $436.10 million. Bruker had a net margin of 4.99% and a return on equity of 27.03%. The business’s revenue was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.23 earnings per share. equities research analysts forecast that Bruker will post 1.38 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 21st. Shareholders of record on Tuesday, September 4th were issued a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a yield of 0.47%. The ex-dividend date of this dividend was Friday, August 31st. Bruker’s dividend payout ratio is presently 13.22%.
Bruker Company Profile
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Further Reading: Should You Consider an Index Fund?
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.